KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Current Deferred Revenue (2016 - 2022)

Emergent BioSolutions' Current Deferred Revenue history spans 13 years, with the latest figure at $15.9 million for Q1 2022.

  • For Q1 2022, Current Deferred Revenue fell 85.9% year-over-year to $15.9 million; the TTM value through Mar 2022 reached $15.9 million, down 85.9%, while the annual FY2021 figure was $16.4 million, 83.62% down from the prior year.
  • Current Deferred Revenue reached $15.9 million in Q1 2022 per EBS's latest filing, down from $16.4 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $118.0 million in Q2 2020 to a low of $9.8 million in Q2 2018.
  • Average Current Deferred Revenue over 5 years is $75.7 million, with a median of $82.1 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 1588.47% in 2018, then crashed 85.9% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $73.1 million in 2018, then grew by 21.61% to $88.9 million in 2019, then rose by 12.6% to $100.1 million in 2020, then crashed by 83.62% to $16.4 million in 2021, then fell by 3.05% to $15.9 million in 2022.
  • Per Business Quant, the three most recent readings for EBS's Current Deferred Revenue are $15.9 million (Q1 2022), $16.4 million (Q4 2021), and $82.1 million (Q3 2021).